SEC Tracker
Get the app
ZYME · XBRL financial data

Zymeworks financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ZYME's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers1717*10191631*2749283*25
Research and development3326*32—————————
General and administrative1715*16161416*17151415*1519
Other operating income (expense)64*6554*3343*1(3)
Operating income (loss)(33)(23)*(38)(43)(34)(22)*(26)(1)(22)(44)*(47)(42)
Other income (expense)0(0)*00(0)(0)*0(0)0(0)*——
Income tax expense (benefit)1(5)*0006*0(0)1(0)*(2)(0)
Net income (loss)(29)(14)*(32)(38)(30)(24)*(23)2(20)(41)*(44)(45)
Earnings per share, basic USD per share(0.41)(0.20)*(0.42)(0.49)(0.39)(0.31)*(0.30)0.03(0.26)(0.55)*(0.59)(0.62)
Earnings per share, diluted USD per share(0.41)(0.20)*(0.42)(0.49)(0.39)(0.31)*(0.30)0.03(0.26)(0.56)*(0.59)(0.62)
Weighted average shares, basic millions of shares7171*76767675*75757675*7573
Weighted average shares, diluted millions of shares7171*76767675*75777673*7573

Balance sheet

CSV

Fiscal quarters (ZYME's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents94158115711226676986541244179
Short-term investments201217——————————
Accounts receivable67193132245625329556
Prepaid and other current assets121918212319171210151622
Total current assets375413394383344300306296292249386298
Property and equipment, net212019181818171616161514
Right-of-use asset181817171717171617161413
Goodwill121212121212121212121212
Total assets556581554516487463426408397347478397
Total current liabilities735657558488653942423647
Lease liability, non-current222221171716151516151413
Total liabilities132116116109120124101747778315317
Accumulated deficit(663)(677)(709)(747)(798)(830)(853)(851)(886)(953)(1,074)(1,171)
Total stockholders' equity42446543840636733932533532026916480
Total liabilities and equity556581554516487463426408397347478397
Common shares outstanding (cover page) millions of shares707171716970707575747371

Cash flows

CSV

Fiscal quarters (ZYME's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(29)(14)*(32)(38)(30)(24)*(23)2(20)(41)*(44)(45)
Stock-based compensation2*3*45*5*5*66*7*9*711*
Net cash from operating activities(43)*14*(38)(25)*(6)*(42)*(3)12*(31)*(10)*(46)(32)*
Purchases of property and equipment1*0*01*1*0*01*0*1*00*
Net cash from investing activities(7)*(1)*(7)(20)*72*(6)*129*0*5*7017*
Proceeds from issuing common stock0*0*——0*0*———year only——
Share repurchases—0*———9*00*16*25*7652*
Net cash from financing activities2*51*21*(15)*(9)*11*(2)*(19)*179(50)*
Net change in cash(48)*63*(43)(44)*51*(56)*1022*(33)*(24)*203(65)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Zymeworks1794.6(32)*71.0M5.6 quarters 10-QJun 30, 2026
Anaptysbio13427*(27)*29.9M6.2 quarters 10-KTJun 30, 2026
Amphastar Pharmaceuticals20520843*42.7M— 10-QSep 30, 2026
ImmunityBio7651(66)*1.1B5.4 quarters 10-QJun 30, 2026
Evoke Pharma124.3(0.5)*1.7M22.2 quarters 10-QSep 30, 2025
Anavex Life Sciences118not reported(9.1)*92.7M13.0 quarters 10-QJun 30, 2026
Stoke Therapeutics10711(63)*65.4M5.2 quarters 10-QSep 30, 2026
Trevi Therapeutics54not reported(17)*142.5M18.3 quarters 10-QJun 30, 2026
Immunome2180(62)*113.6M8.4 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.